PRICE T ROWE ASSOCIATES INC /MD/ - RECURSION PHARMACEUTICALS IN ownership

RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 128 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2021. The put-call ratio across all filers is 1.27 and the average weighting 1.8%.

Quarter-by-quarter ownership
PRICE T ROWE ASSOCIATES INC /MD/ ownership history of RECURSION PHARMACEUTICALS IN
ValueSharesWeighting
Q3 2023$406
-29.3%
52,975
-31.0%
0.00%
Q2 2023$574
+15.0%
76,826
+2.7%
0.00%
Q1 2023$499
-14.7%
74,793
-1.5%
0.00%
Q4 2022$585
-99.8%
75,919
+109.7%
0.00%
Q3 2022$386,000
+107.5%
36,206
+58.8%
0.00%
Q2 2022$186,000
-95.4%
22,800
-95.9%
0.00%
Q1 2022$4,025,000
-72.6%
562,190
-34.4%
0.00%
-100.0%
Q4 2021$14,690,000
+9.9%
857,573
+47.7%
0.00%0.0%
Q3 2021$13,361,000
-37.2%
580,670
-0.4%
0.00%
-50.0%
Q2 2021$21,283,000583,0850.00%
Other shareholders
RECURSION PHARMACEUTICALS IN shareholders Q4 2021
NameSharesValueWeighting ↓
Obvious Management Services, L.L.C. 3,985,087$42,401,000100.00%
Two Sigma Ventures, LP 903,400$9,612,000100.00%
DCVC Opportunity Fund II GP, LLC 3,951,141$42,040,00054.37%
Data Collective IV GP, LLC 5,941,120$63,214,00049.97%
MIC Capital Management UK LLP 8,451,758$89,927,00016.21%
MV Management XI, L.L.C. 1,971,908$20,981,00015.20%
ArchPoint Investors 1,116,126$11,876,0004.85%
HARVARD MANAGEMENT CO INC 1,509,254$16,058,0002.00%
PLATINUM INVESTMENT MANAGEMENT LTD 2,251,971$23,961,0001.00%
Duquesne Family Office 1,385,950$14,747,0000.84%
View complete list of RECURSION PHARMACEUTICALS IN shareholders